Therapeutic strategies according to the site of thrombosis in real life from the International Registry on Splanchnic Vein Thrombosis study*
| Strategy . | BCS (N = 51) . | PVT (N = 244) . | MVT (N = 67) . | SpVT (N = 19) . | Multiple sites (N = 232) . |
|---|---|---|---|---|---|
| No treatment | 31.4% | 33.2% | 9.0% | 15.8% | 12.9% |
| UFH | 15.7% | 4.9% | 9.0% | — | 16.4% |
| LMWH/fonda | 49.0% | 58.6% | 83.6% | 84.2% | 71.8% |
| VKA | 47.1% | 31.6% | 61.2% | 63.2% | 60.8% |
| Thrombolysis | 3.9% | — | 1.5% | — | 2.6% |
| Surgery | — | — | 7.5% | — | 6.5% |
| Antiplatelets | — | 1.6% | — | — | — |
| Interventional procedures | 7.8% | 1.6% | — | — | 0.9% |
| Strategy . | BCS (N = 51) . | PVT (N = 244) . | MVT (N = 67) . | SpVT (N = 19) . | Multiple sites (N = 232) . |
|---|---|---|---|---|---|
| No treatment | 31.4% | 33.2% | 9.0% | 15.8% | 12.9% |
| UFH | 15.7% | 4.9% | 9.0% | — | 16.4% |
| LMWH/fonda | 49.0% | 58.6% | 83.6% | 84.2% | 71.8% |
| VKA | 47.1% | 31.6% | 61.2% | 63.2% | 60.8% |
| Thrombolysis | 3.9% | — | 1.5% | — | 2.6% |
| Surgery | — | — | 7.5% | — | 6.5% |
| Antiplatelets | — | 1.6% | — | — | — |
| Interventional procedures | 7.8% | 1.6% | — | — | 0.9% |
Modified from Ageno et al6 with permission.
fonda, fondaparinux; LMWH, low-molecular weight heparin; PVT, portal vein thrombosis; UFH, unfractionated heparin; SpVT, splenic vein thrombosis VKA, vitamin K antagonists.